Omnitrope

ApprovedSmall molecule

Novartis

Omnitrope is one of 37 small molecule programs targeting Small for gestational age. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Small for Gestational AgeActive, not recruiting

Growth Hormone DeficiencyActive, not recruiting

Adult Growth Hormone DeficiencyCompleted

Small for Gestational AgeApproved

Active, not recruiting

Growth Hormone DeficiencyPhase 2

Active, not recruiting

Adult Growth Hormone DeficiencyPhase 2

Completed

Competition

Competitive Landscape

51 competitors in Growth Hormone Deficiency

#DrugCompanyPhaseTrials

Genotropin

EMD Serono

Approved

24 2

Nutropin AQ

Roche

Approved

1 3

Recombinant Human Growth Hormone

Changchun GeneScience Pharmaceutical Co., Ltd.

Approved

5 4

Saizen

Merck & Co.

Phase 3

3 5

Omnitrope

Novartis

Approved

2 6

PEG-Somatropin

Changchun GeneScience Pharmaceutical Co., Ltd.

Approved

8 7

Norditropin

Novo Nordisk

Phase 3

2 8

Macrilen

AAEterna Zentaris

Phase 3

1 9

Genotropin

Pfizer

Phase 2

6 10

LUM-201

LLumos Pharma

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Small for gestational age1 trial

Safety and Efficacy of Omnitrope® (rhGH) in Short Children Born Small for Gestational Age (SGA)

Completed· Novartis logo

Novartis·Phase 4·NCT00537914·278 enrolled

Adult Growth Hormone Deficiency1 trial

A Phase 2, Multiple Dose, Open-Label, Parallel-Group, Active Controlled, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACP-001 in Adult Patients With Growth Hormone Deficiency

Completed·AAscendis Pharma A/S·Phase 2·NCT01247675·37 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Omnitrope. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Omnitrope compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Omnitrope. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novartis

Omnitrope

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Small for gestational age1 trial

Adult Growth Hormone Deficiency1 trial

References

Drug Info

Quick Facts

Related News